Cargando…
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
PURPOSE: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry....
Autores principales: | Novakova-Jiresova, Alena, Kopeckova, Katerina, Boublikova, Ludmila, Chloupkova, Renata, Melichar, Bohuslav, Petruzelka, Lubos, Finek, Jindrich, Fiala, Ondrej, Grell, Peter, Batko, Stanislav, Linke, Zdenek, Kiss, Igor, Prausova, Jana, Buchler, Tomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342462/ https://www.ncbi.nlm.nih.gov/pubmed/32753954 http://dx.doi.org/10.2147/CMAR.S255332 |
Ejemplares similares
-
Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
por: Buchler, Tomas, et al.
Publicado: (2018) -
Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
por: Fiala, Ondrej, et al.
Publicado: (2020) -
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
por: Lakomy, Radek, et al.
Publicado: (2017) -
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
por: Slavicek, Lubomir, et al.
Publicado: (2014) -
Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry
por: Poprach, Alexandr, et al.
Publicado: (2020)